Advertisement

Topics

Latest Drug Discovery NewsRSS

05:56 EDT 22nd September 2017 | BioPortfolio

Krystal Microplate Enables Development of Drug Testing Assay for Plasmodium vivax

Porvair Sciences reports that the National Center for Biological Sciences (NCBS) in Bangalore, India is using its Krystal 384 black microplate to produce a standard drug testing assay for Plasmodium vivax infection. The NCBS is a leading national institute whose faculty members undertake research in the frontier areas of biology. Scientists at the NCBS use experimental and computational approaches...

Cholesterylester Transfer Protein CETP Inhibitor Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1500

DelveInsight's, Cholesterylester Transfer Protein CETP InhibitorMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Cholesterylester Transfer Protein CETP Inhibitor. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative p...

Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy

Opdivo is the first and only Immuno-Oncology treatment to demonstrate survival benefit in patients who underwent two or more prior treatments Opdivo is the first Immuno-Oncology agent anywhere in the world to receive approval for unresectable advanced or recurrent gastric cancer based on a Phase 3 study Bristol-Myers

STAT Plus: Zapping the brain for stroke rehab: Pivotal clinical trial begins

Despite being forced by Hurricane Irma to close its outpatient facilities for several days, the Mayo Clinic in Jacksonville, Fla., is expected to forge ahead this month with a pivotal…

To advance medicine’s future, the NIH tries to win the trust of communities mistreated in the past

The agency hopes to recruit more than a half-million people from communities that are underrepresented in science — and wary of clinical research.

Cystic Fibrosis Global Clinical Trials Review, H2, 2017 [Report Updated: 19072017] Prices from USD $2500

Cystic Fibrosis Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial report, Cystic Fibrosis Global Clinical Trials Review, H2, 2017" provides an overview of Cystic Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cystic Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries c...

ZEUS Scientific Announces U.S. FDA Premarket Approvals (PMA) and Launch of its ZEUS ELISA™ Parvovirus B19 Test Systems

Designed to significantly improve laboratory’s processing turnaround time and productivity with excellent precision and accuracy Branchburg, NJ, USA (PRWEB) September 22, 2017 ZEUS Scientific, a leading global diagnostic solutions company, today announced the launch of ZEUS ELISA Parvovirus B19 IgG and IgM Test Systems, following receipt of Premarket Approvals (PMA) from the U.S. Food and Drug ...

Skin Medication Matrix Targets Venous Leg Ulcer Healing in New USA Clinical Trial

Qualified participants will receive all trial related care and financial compensation for time and travel. No insurance is required. United States (PRWEB) September 22, 2017 The effectiveness of a new wound healing skin medication for venous leg ulcers is now being assessed in clinical trials in the United States. (clinicaltrials.gov : NCT02973893) To find out more about this clinical trial pleas...

FDAnews Announces: Early Bird Pricing Ends Sept. 29 for Drug Quality Risk Management, Oct. 26-27, 2017, Arlington, VA

In two information-packed days at the Drug Quality Risk Management workshop, drugmakers will go from learning the basics of ICH Q9 to applying its subtleties. They’ll use case studies and participate in role-playing exercises, small-group simulations and more, that will help them understand how to integrate Quality Risk Management into their operation. Falls Church, VA (PRWEB) September 22, 2017...

AlphaSynuclein alphaSyn or SNCA Inhibitor Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1250

DelveInsight's, AlphaSynuclein alphaSyn or SNCA InhibitorMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across AlphaSynuclein alphaSyn or SNCA Inhibitor. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therap...

DNA Sequencing technologies,markets and companies [Report Updated: 08092017] Prices from USD $4000

SummaryThis report briefly reviews basics of human genome variations, development of sequencing technologies, and their applications. Current large and small sequencers are described as well as companies developing them. Various applications of sequencing are described including those for genetics, medical diagnostics, drug discovery and cancer. Next generation sequencing technologies, both second...

Multiple Myeloma Research Foundation Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 22082017] Prices from USD $250

SummaryMultiple Myeloma Research Foundation MMRF is a nonprofit foundation that develops advanced multiple myeloma treatments. The foundation provides endtoend solutions for drug discovery and development targeting multiple myeloma. It provides clinical trails such as molecularly targeted therapies, immune therapies and noval therapies. MMRF's offers educational programs for people suffering from ...

New ‘Yes on Issue 2’ TV Ad Tells Truth About Michael Weinstein

Big Drug Companies Have Spent Millions of Dollars to Demonize an International Humanitarian The Yes on Issue 2 Campaign has launched a new ad to tell the truth about international humanitarian and leader of the nonprofit AIDS Healthcare Foundation Michael Weinstein. The ad comes as big drug companies are spending millions of dollars to carpet Ohio airw...

Cardiovascular Drug Delivery technologies,markets and companies [Report Updated: 08092017] Prices from USD $2800

SummaryDrug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients to all organs of the body. Drugs can be introduced into the vascular system for systemic effects or targeted to an organ via the regional blood supply. In addition to the usual formulations of drugs such as contr...

Global Blood Therapeutics Inc GBT Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryGlobal Blood Therapeutics Inc GBT is a clinicalstage biopharmaceutical company that discovers, develops and commercializes novel oral medicines for the treatment of grievous bloodbased disorders. The company's lead drug candidate GBT440 is an oral, small molecule drug for the treatment of sickle cell disease SCD is in Phase II clinical trial statge. Its GBT440 is a hemoglobin modifier which...

CORRECTING and REPLACING Synergy Pharmaceuticals to Present at Upcoming September Investor Conferences

In the release dated September 6, 2017, the presentation date and time for the Cantor Fitzgerald Global Healthcare Conference should be changed to Wednesday, September 27, 2017 at 9:45 a.m. Eastern Time (instead of Monday, September 25, 2017 at 10:20 a.m. Eastern Time). The corrected release reads: SYNERGY PHARMACEUTICALS TO PRESENT AT UP...

Glucocorticoid Receptor GR Antagonist Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1250

DelveInsight's, Glucocorticoid Receptor GR AntagonistMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Glucocorticoid Receptor GR Antagonist. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therapeutics a...

D1 Agonist Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1250

DelveInsight's, D1 AgonistMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across D1 Agonist. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therapeutics assessment of D1 Agonist by development stage, therapy ...

Interleukin23 IL23 Inhibitor Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1500

DelveInsight's, Interleukin23 IL23 InhibitorMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Interleukin23 IL23 Inhibitor. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therapeutics assessment of Inter...

Quantum Health Introduces USDA Organic Cough Relief Lozenges and TheraZinc Lozenges for Immune Support*

Quantum Health, makers of effective health and personal care products inspired by nature, has launched a new line of wellness lozenges for cough relief and immune support*. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170921006199/en/ USDA Organic Cough Relief Lozenges and TheraZinc Lozenges (Ph...

MilliporeSigma Opens China's First BioReliance® End-to-End Biodevelopment Center in Shanghai

- Company's first end-to-end center outside of Europe - Accelerates clinical development from molecule to commercial production BILLERICA, Mass., Sept. 22, 2017 /PRNewswire/ -- MilliporeSigma today announced the opening of its first BioReliance® End-to-End Biodevelopment Center in the Asia Pacific (APAC) region. Located in Shanghai, China, the center will provide a full range of pro...

Putting Patients at the Heart of the Process

Festival of Genomics Boston opens its doors to patients. From October 3-4, 2017, Festival of Genomics Boston will welcome key figures from biotech, healthcare, drug development and academic research. The convention gathers to present recent developments in human genomics, and discuss the challenges applying them to healthcare. This year, the organisers...

Recipharm AB RECI B Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryRecipharm AB Recipharm is a contract manufacturing organization that offers manufacturing, and development and technology services. The organization's manufacturing segment provides contract manufacturing of pharmaceuticals such as semisolids, and oral liquids, solid dose, sterile products, besides clinical trial materials including APIs and other drugs. Recipharm's development and technolo...

Q&A: PerceptiMed’s Maione talks engaging patients through Rx tech

Drug Store News spoke to PerceptiMed chief business officer Frank Maione about how PerceptiMed is working to help pharmacies deliver on the goal of improved patient engagment.  read more

iMedicare, Mirixa partner on new integration

David SalazarThe integration of iMedicare’s plan comparison platform into Mirixa’s MirixaPro platform will enable pharmacies to take advantage of medication-related opportunities within their everyday workflow by prioritizing available clinical interventions for each specific patient. read more

Quick Search
Advertisement
 

review and buy Drug Discovery market research data and corporate reports here